{"prompt": "['Aimmune Therapeutics, Inc.', 'AR101', 'ARC009 Protocol Amend 1.0', '11 Apr 2018 - FINAL', 'Aimmune Confidential Information', 'Page 36 of 122', 'An epinephrine auto-injector device will be provided or prescribed as appropriate to subjects', 'and parents/caregivers who do not have one. The expiration date and record of training on', \"the epinephrine auto-injector device must be documented in the subject's source documents.\", '5.2.6 Unscheduled Visit Procedures', 'Unscheduled visit procedures are listed in each schedule of activities. Other study', 'procedures may be performed as clinically appropriate.', 'Unscheduled visits may be performed anytime to assess or follow up adverse events, or at the', 'request of the subject or investigator. The date and reason for the unscheduled visit must be', 'recorded in the source documentation.', '5.3', 'Early Discontinuation', 'Subjects receiving AR101 treatment: Early treatment discontinuation is defined as', 'permanent cessation of study product administration anytime before completing AR101', 'maintenance treatment at 300 mg/day for approximately 12 months. Subjects who', 'discontinue early will have early discontinuation procedures approximately 14 days after', 'their last dose of AR101 according to the schedule of activities.', 'Subjects with unresolved adverse events at early discontinuation will have safety follow-up', 'per Section 5.5.', 'Temporary treatment interruption (eg, due to an adverse event) will not be considered early', 'discontinuation.', 'Subjects receiving standard of care alone: Early discontinuation of observation is defined as', 'cessation of study participation anytime before the scheduled exit visit. Subjects who', 'discontinue early will have early discontinuation procedures according to the schedule of', 'activities. Subjects with unresolved adverse events at early discontinuation will have safety', 'follow-up per Section 5.5.', 'The primary reasons for early discontinuation of AR101 treatment or observation are listed in', 'Table 5.']['Aimmune Therapeutics, Inc.', 'AR101', 'ARC009 Protocol Amend 1.0', '11 Apr 2018 - FINAL', 'Aimmune Confidential Information', 'Page 37 of 122', 'Table 5: Primary Reasons for Early Discontinuation', 'Category', 'Reason', 'Comment', 'Protocol/Investigator-Initiated', 'Adverse event or', 'Any intolerable adverse event that cannot be ameliorated using adequate', 'intercurrent illness', 'medical intervention or that in the opinion of the investigator or sponsor', 'may lead to undue risk if AR .101 treatment were continued, such as the', 'following:', 'Life-threatening symptoms (CoFAR grade 4), including anaphylaxis', 'resulting in hypotension, neurologic compromise, or mechanical', 'ventilation secondary to study treatment or food challenge.', 'Severe dose-related allergic hypersensitivity symptoms (CoFAR', 'grade 3) that require intensive therapy (per investigator assessment, but', 'may include interventions such as IV epinephrine, intubation, or', 'admission to an intensive care unit) or are recurrent.', 'Poor control or persistent activation of secondary atopic disease', '(eg, atopic dermatitis, asthma).', 'Development of biopsy-documented eosinophilic esophagitis.', 'Any adverse event that meets the early discontinuation criteria for study', 'product tolerability or delays as follows:', 'Tolerability of study product:', '- Moderate or dose-limiting symptoms at < 3 mg or severe symptoms', 'at any dose on initial dose-escalation day 1 and 2', '- The dose was withheld for > 4 weeks for chronic or recurrent', 'gastrointestinal adverse events at VI 20 mg/day', '- Unable to reach the 300 mg/day dose within 40 weeks of up-dosing', '- Unable to tolerate at least 300 mg of peanut protein at the OLFC', 'Use of rescue medications:', '- Treatment with epinephrine, beta-agonist, oxygen, IV fluids,', '> 2 doses of antihistamines, and/or glucocorticosteroids at any', 'AR101 dose (including 6 mg) on initial dose-escalation days 1 and 2', '- Treatment with > 2 doses of epinephrine for dose-related allergy', 'symptoms anytime', 'Dose adjustment of study product:', '- Unable to escalate the dose level after 3 consecutive failed attempts', 'with at least 2 weeks between each escalation attempt', '- Unable to tolerate 3 attempts at dose reduction after the occurrence', 'of mild or moderate allergy symptoms, or unable to tolerate', '1 attempt at dose reduction after the occurrence of severe symptoms', '- Missed > 15 consecutive days of study product dosing due to', 'medically indicated circumstances (eg, as part of the treatment for', 'an intercurrent adverse event); missed doses per dose adjustment', 'guidelines in Section 8.5.3.2 are allowed.', 'Use of prohibited', 'Prohibited concomitant medications are listed in Section 7.4.', 'medication', 'Pregnancy', 'Pregnancy will be followed to delivery or until termination of the', 'pregnancy (Section 8.5.7.2).', 'Death']['Aimmune Therapeutics, Inc.', 'AR101', 'ARC009 Protocol Amend 1.0', '11 Apr 2018 - FINAL', 'Aimmune Confidential Information', 'Page 38 of 122', 'Category', 'Reason', 'Comment', 'Investigator decision', \"Investigators may elect to discontinue a subject's study treatment if they\", \"decide it is in the subject's best interest. Select this category if adverse\", 'events/intercurrent illness, use of prohibited concomitant therapy, or', 'noncompliance do not apply and the subject preferred to continue', 'treatment.', 'Major noncompliance with', 'The medical monitor or investigator may request early discontinuation in', 'protocol', 'the event of a major protocol deviation, lack of cooperation, or', 'noncompliance.', 'Noncompliance with study product is defined as missed doses for', '8 consecutive days, or missed doses for > 3 consecutive days on', '> 3 occasions during up-dosing (Section 8.5.5).', 'Dropout', 'Subject decision', 'Active discontinuation choice by the subject.', 'Subjects may permanently discontinue study treatment anytime for any', 'reason.', 'Sponsor-Initiated', 'Sponsor discontinuation of', 'The sponsor reserves the right to terminate the study anytime for any reason', 'study', 'as described in Section 13.6. The sponsor will terminate this study', 'following completion of the study objectives, or earlier if deemed', 'necessary.', 'Loss to Follow-Up', 'Loss to follow-up', 'Cessation of participation without notice or action by subject.', 'Loss to follow-up procedures are described in Section 5.6.', 'CoFAR, Consortium of Food Allergy Research; IV, intravenous; OLFC, open-label food challenge.', '5.3.1', 'Follow-Up HRQOL Questionnaires for Subjects Receiving AR101 Treatment', 'Who Discontinue Early', 'Subjects receiving AR10 treatment who discontinue early from the study and their', 'parents/caregivers will complete questionnaires at early discontinuation according to', 'Appendix 4 and Appendix 5. In addition, the subject and parent/caregiver will complete the', 'relevant follow-up EQ-5D, Food Allergy Quality of Life Questionnaire (FAQLQ), and Food', 'Allergy Independent Measure (FAIM) questionnaires thereafter according to the timing', 'shown in Table 6 and as indicated in Appendix 4 and Appendix 5.']['Aimmune Therapeutics, Inc.', 'AR101', 'ARC009 Protocol Amend 1.0', '11 Apr 2018 - FINAL', 'Aimmune Confidential Information', 'Page 39 of 122', 'Table 6: Follow-Up HRQOL Questionnaires for Subjects Receiving AR101 Treatment', 'Who Discontinue Early', 'Follow-Up EQ-5D, FAQLQ, and FAIM', 'Timing of Early Discontinuation', 'Questionnaires', 'Before the start of maintenance', 'Complete at 12 months and 18 months after day 1', 'After less than 9 months of maintenance (ie, between', 'Complete at 18 months after day 1', 'maintenance visit week 1 and 41)', 'EQ-5D, European Quality of Life 5-Dimensions health questionnaire; FAIM, Food Allergy Independent', 'Measure; FAQLQ, Food Allergy Quality of Life Questionnaire.', '5.4', 'Study Exit', 'Study exit procedures are listed in the schedules of activities.', 'Completion of study exit procedures will be considered as completing the study.', 'Subjects with unresolved adverse events at study exit or who had GI adverse events of', 'interest will have safety follow-up per Section 5.5.', 'After the study exit procedures are completed, AR101-treated subjects will have the option to', 'enroll in an open-label follow-on study to continue AR101 treatment until it becomes', 'commercially available or development is terminated. Subjects who received standard of', 'care alone will also have the option to receive AR101 treatment in a follow-on study.', 'Subjects may continue to receive AR101 maintenance treatment or standard of care alone in', 'ARC009 if the open-label follow-on study is not activated at their study site when subjects', 'complete their course of treatment/observation.', '5.5 Safety Follow-Up', 'Safety follow-up procedures are listed in Appendix 7.', 'Safety follow-up is for subjects with unresolved adverse events at early discontinuation or', 'study exit, or who had GI adverse events of interest. Safety follow-up will continue until the', 'ongoing adverse events resolve or stabilize (after at least 30 days of follow-up after the early', 'discontinuation or exit visit), the subject withdraws consent for follow-up, or the study is', 'terminated. Safety follow-up will continue for 6 months after early discontinuation or study', 'exit for subjects with GI adverse events of interest as described in Section 5.5.1.', 'For subjects who refuse to come to the study site or if safety follow-up cannot be obtained', 'from alternate contacts, telephone contact must be attempted and documented to review for', 'adverse events. The procedures for loss to follow-up will be followed for subjects who do', 'not respond to telephone calls (Section 5.6).']", "completion": ""}